Free Trial
→ Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.62
-1.7%		$0.94
$0.62
▼
$11.15
$10.54M-1.73947,887 shs66,095 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-0.03%-17.53%-16.45%-34.27%-94.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.62
-1.7%		$0.94
$0.62
▼
$11.15
$10.54M-1.73947,887 shs66,095 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-0.03%-17.53%-16.45%-34.27%-94.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest TPST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)

Latest TPST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.32N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
416.89 million10.78 millionNo Data

Recent News About These Companies

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
October 14 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3380659/0/en/tempest-appoints-john-w-frederick-to-board-of-directors-strengthening-financial-and-capital-markets-expertise.html
Tempest Therapeutics (NASDAQ:TPST) Upgraded to Sell at Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104264
Tempest Therapeutics consensus price target decreased by 36.36% to $7.14
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tempest-therapeutics-consensus-price-target-decreased-by-36-36-to-7-14/ar-AA2dnCAC
Tempest Therapeutics names Nancy Freda-Smith to its board
September 23, 2026  |  streetinsider.comhttps://www.streetinsider.com/Board+Changes/Tempest+Therapeutics+names+Nancy+Freda-Smith+to+its+board/27093511.html
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367428/0/en/tempest-appoints-global-finance-leader-nancy-freda-smith-to-board-of-directors.html
Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69591841-tempest-therapeutics-tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t-platform-399.htm
Tempest Stock Exploded on a CAR-T Option Most Investors Had Never Heard Of
September 16, 2026  |  moneymorning.comM
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
September 16, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61809066/why-tempest-therapeutics-shares-are-trading-higher-by-around-50-here-are-20-stocks-moving-premarket?utm_source=snapi
Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691311/tempest-gets-option-to-license-cd7-targeted-in-vivo-car-t-platform-overnight-stock-surge-64.aspx
Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Tempest+Therapeutics+options+CD7+lentiviral+CAR-T+platform+from+Senlang/27064842.html
Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tempest-therapeutics-gains-option-license-214530532.html
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362637/0/en/tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t-platform.html
Tempest Therapeutics announces $2.5M private placement
September 11, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/tempest-therapeutics-announces-25m-private-placement/ar-AA2c1rwV
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360287/0/en/tempest-therapeutics-announces-up-to-7-5-million-private-placement.html
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357654/0/en/tempest-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
August 13, 2026  |  quiverquant.comQ
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344974/0/en/tempest-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330290/0/en/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-t.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$0.62 -0.01 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$0.63 +0.00 (+0.45%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas